Part 6/Chapter 42/20-min read

Amputation, Rehabilitation, Prosthetics, and Palliative Limb Care

Major amputation as a deliberate vascular endpoint rather than the opposite of vascular care: when an operation, endovascular procedure, primary amputation, rehabilitation pathway, or palliative limb plan is most likely to produce a healed, useful, goal-concordant outcome. The chapter frames level selection, prosthetic planning, and palliative limb care.

Listen to this chapter10 min · AI audio edition · two hostsAI narration

Multidisciplinary board: A board-room discussion with roles, escalation triggers, surveillance, patient goals, and what makes the pathway coherent.

Choose the hosts

Amputation is a vascular decision

Major amputation is not the opposite of vascular care; it is one of its deliberate endpoints. In chronic limb-threatening ischemia and acute limb ischemia, the vascular surgeon must decide whether an operation, endovascular procedure, amputation, rehabilitation pathway, or palliative limb plan is most likely to produce a healed, useful, and goal-concordant outcome. Contemporary PAD and CLTI guidelines place primary amputation and palliation inside the same decision framework used for revascularization, particularly when the limb is unsalvageable, procedural risk is prohibitive, life expectancy is limited, or the expected functional benefit of salvage is poor.

TreatmentSalvage vs primary amputation vs secondary amputation vs palliation decision
  • Treat major amputation as a deliberate, multidisciplinary CLTI decision: confirm anatomy, salvage attempts, infection control, and goals-of-care before proceeding.
    Trigger
    Adults with CLTI, severe foot infection, ALI, or failed limb-salvage attempts.
    Branch / Endpoint
    Framework-level guidance for primary-amputation and palliative-care triggers; recommendation grades differ between guideline societies
    Citation
  • Apply the European framework: multidisciplinary CLTI review with explicit consideration of primary amputation and palliative limb care when revascularization is futile or against patient goals.
    Trigger
    Adults with CLTI or ALI under European guideline frameworks, including those approaching primary amputation or palliative care.
    Branch / Endpoint
    Citation
  • The Global Vascular Guidelines keep primary amputation and palliation inside the CLTI decision framework for patients with unsalvageable limbs, prohibitive risk, limited life expectancy, or poor expected functional benefit, rather than treating amputation as a failure outside vascular planning.
    Trigger
    Vascular patients
    Branch / Endpoint
    Citation
Guideline note

Limb-salvage, MALE, and amputation outcome evidence

  1. AMPREDICT More VA Cohort United States VA · 2025· Multinomial prediction model derived and externally validated in single-system EHR cohort
    AMPREDICT MoRe (n=9,221 VA amputees 2015-2021) reports a 1-year post-incident-amputation outcome distribution of 57.7% no death/no re-amputation, 22.9% no death/re-amputation, 14.3% death/no re-amputation, and 5.1% death plus re-amputation; the EHR-only prediction model achieved M-index 0.70 overall and c=0.82 for no-event vs both-events discrimination.
    Applies to
    Adults with incident unilateral transmetatarsal, transtibial, or transfemoral amputation secondary to diabetes or peripheral artery disease (US Veterans Affairs cohort).
    Boundary
    Single-system VA cohort, mostly male; generalisability to civilian, female, and non-US populations needs validation. Model not yet implemented as decision support and predicts 1-year only.
Source

For surgical trainees, the first discipline is to stop treating amputation as a “failed salvage” label and instead document why a limb-salvage pathway is or is not anatomically, physiologically, and personally appropriate. The 2024 multisociety PAD framework expects amputation decision-making to sit within the broader CLTI pathway, with either limb-salvage attempts documented or anatomy and comorbidity recorded as reasons revascularization is not expected to succeed.

The second discipline is to define what “success” means before committing to another procedure. BEST-CLI and BASIL-2 show that, in contemporary distal CLTI, revascularization strategy affects trajectories that include major limb events, amputation, and death; these trials should make the surgeon cautious about offering repeated salvage attempts when the realistic endpoint is a nonhealing limb, a prolonged hospital course, or delayed amputation without meaningful recovery.

Limb salvage and amputation endpoint evidence
  • Population
    Adults with CLTI and infrainguinal PAD, including those considered for primary amputation when limb-salvage success is uncertain.
    Intervention
    BEST-CLI MALE-or-death rates define the contemporary boundary at which limb-salvage attempts compete with primary or secondary amputation, interpreted with cohort-specific framing rather than pooled superiority claims.
    Comparator
    Endovascular revascularization
    Key result
    BEST-CLI Cohort 1 (n=1,420 with adequate single-segment great saphenous vein) at median 2.7-year follow-up reported a 42.6% surgical-arm and 57.4% endovascular-arm composite of major adverse limb event (which includes above-ankle amputation) or death, defining the contemporary boundary at which limb-salvage attempts compete with primary or secondary amputation
    Limitation
    Major adverse limb event definition includes above-ankle amputation and reintervention; numbers cannot be interpreted as pure amputation-rate estimates without parsing the disaggregated endpoint definition.
    Citation
  • Population
    Patients with CLTI after infrainguinal revascularization where MALE and amputation endpoints frame limb-salvage outcomes.
    Intervention
    Use the MALE definition from BEST-CLI when discussing amputation outcomes after revascularization in the amputation chapter.
    Comparator
    BEST-CLI established MALE (major adverse limb event including amputation) as a composite endpoint, providing the framework for distinguishing limb-salvage success from progression to amputation.
    Key result
    MALE is a composite endpoint, so its components may not all carry equal clinical weight.
    Limitation
  • Population
    Adults with CLTI requiring infra-popliteal revascularization; includes a subset who proceed to major amputation despite revascularization.
    Intervention
    In infra-popliteal CLTI, the choice between bypass-first and endovascular-first strategy directly shapes the amputation-or-death endpoint, with BASIL-2 favoring endovascular-first against BEST-CLI's surgical-first signal.
    Comparator
    45% endovascular-first, illustrating that strategy choice in distal CLTI directl
    Key result
    BASIL-2 (n=345 with CLTI requiring an infra-popliteal revascularization) reported a composite of major amputation or death adjusted HR 1.35 favoring endovascular-first and mortality of 53% bypass-first vs 45% endovascular-first, illustrating that strategy choice in distal CLTI directly affects amputation-or-death trajectories
    Limitation
    European pragmatic trial; differs from BEST-CLI in anatomy and conduit-eligibility definitions. Do not merge BASIL-2 amputation rates with BEST-CLI Cohort 1 results.
    Citation

The third discipline is to counsel with outcome ranges rather than reassurance. Population data show large variation in major lower-limb amputation incidence and early mortality across health systems, while contemporary amputation cohorts and systematic mortality syntheses support frank discussion that major lower-extremity amputation is a life-altering operation with substantial perioperative and long-term risk.

Risk prediction should support, not replace, judgment. AMPREDICT MoRe, using a large VA cohort of incident dysvascular amputees, reported 1-year outcomes of no death/no re-amputation in 57.7%, no death/re-amputation in 22.9%, death/no re-amputation in 14.3%, and both death plus re-amputation in 5.1%; its EHR-only model performed moderately overall and better for distinguishing no-event from both-event outcomes, but it remains a single-system, mostly male VA model and is not yet a bedside decision-support mandate.

Level selection must heal and function

Level selection is the central operative judgment in dysvascular amputation: the operation must remove the nonviable or nonfunctional limb segment, but the residual limb must also have a realistic chance of healing and supporting rehabilitation. Current rehabilitation guidance supports pre-amputation evaluation, prosthetic candidacy assessment, residual-limb planning, and longitudinal rehabilitation pathways, so the amputation level should be chosen with both wound healing and downstream function in view.

Guideline comparison

Amputation-level worksheet: healing likelihood, function, and re-amputation risk

  1. Va/dod Amputation Rehabilitation Clinical Practice Guideline United States Va/dod · 2017
    Official rehabilitation guideline supports pre-amputation, prosthetic candidacy, residual-limb and longitudinal rehab pathways.
    Applies to
    Official rehabilitation guideline supports pre-amputation, prosthetic candidacy, residual-limb and longitudinal rehab pathways.
    Boundary
    Reflects guideline recommendations; consult the source guideline for exact class and level-of-evidence wording.
  2. Danish Nationwide Major-Lea Re-Amputation Cohort Denmark National Registry · 2024
    Nationwide Danish cohort on re-amputation risk and timing after major LEA; primary evidence registry source
    Applies to
    Nationwide Danish cohort of patients undergoing major lower-extremity amputation, evaluated for re-amputation risk and timing
    Boundary
    Registry data from a single national cohort; associations do not establish causation and may not generalise beyond that setting.
Source ·

Through-knee and above-knee choices should be presented as distinct surgical strategies rather than interchangeable “major amputation” labels. Comparative outcomes work on through-knee versus above-knee amputation supports treating this as a specific technique and level-choice decision, especially when the patient’s rehabilitation potential, residual-limb needs, and probability of healing are being weighed.

Guideline note

Through-knee vs above-knee amputation outcomes

  1. Through-Knee Vs Above-Knee Amputation Outcomes International Cohort · 2022
    Through-knee versus above-knee amputation outcomes (vascular and non-vascular); primary evidence surgical-technique comparison source
    Applies to
    Patients undergoing through-knee versus above-knee amputation, across vascular and non-vascular indications
    Boundary
    Cohort comparison spanning vascular and non-vascular indications; observational data do not establish causation.
Source

The decision is rarely “lowest possible level” versus “highest safe level.” A distal level that preserves length but fails to heal may expose the patient to repeated operations, prolonged immobility, and delayed rehabilitation. Conversely, a more proximal level may heal more reliably but reduce functional potential. Re-amputation risk and timing are therefore not secondary details; they are part of the first consent conversation and should be incorporated into the level-selection discussion.

Guideline comparison

ACC/AHA multisociety PAD guideline

What guidance applies?

  1. ACC/AHA Multisociety PAD Guideline North America · 2024
    The 2024 multisociety PAD guideline frames amputation decision-making within the broader CLTI care pathway, requiring documented limb-salvage attempts or anatomy/comorbidity precluding revascularization.
    Applies to
    Patients with CLTI in whom amputation is being considered after limb-salvage attempts or because anatomy/comorbidity precludes revascularization.
    Boundary
    Reflects guideline recommendations; consult the source guideline for exact class and level-of-evidence wording.
  2. ESC Pad/aortic Guideline Europe ESC · 2024· European Society of Cardiology guideline
    The 2024 ESC PAD/aortic guideline addresses major amputation and palliative limb care within its CLTI framework, recommends a multidisciplinary team approach to limb-threatening disease, and emphasises that primary amputation can be appropriate when revascularization is futile or contrary to patient goals.
    Applies to
    Adults with CLTI or ALI under European guideline frameworks, including those approaching primary amputation or palliative care.
Source ·

Best medical therapy does not stop at the amputation incision. The CLTI guidelines require antithrombotic therapy, lipid lowering, blood-pressure and glycemic control, counseling, exercise where appropriate, preventive foot care, and surveillance pathways across CLTI care, including patients who are not undergoing revascularization or who are approaching major amputation.

Recovery planning starts before discharge

Rehabilitation begins before the patient leaves the vascular service. A major amputation admission should include early identification of prosthetic candidacy, residual-limb needs, functional goals, discharge destination, and longitudinal rehabilitation follow-up; official rehabilitation guidance supports these pre-amputation, prosthetic, residual-limb, and long-term pathways.

The vascular surgeon’s role is to make the rehabilitation plan surgically coherent. The residual limb, wound-healing plan, medication plan, surveillance plan, and expected mobility pathway should be communicated before discharge so that rehabilitation teams are not forced to infer operative intent. Dysvascular rehabilitation cohort data support counseling patients that functional recovery and prosthetic training are realistic goals for selected patients, but not automatic outcomes for every patient after major amputation.

Discharge counseling should include the possibility of re-amputation and death within the first postoperative year. AMPREDICT MoRe provides a clinically useful way to discuss competing outcomes after incident dysvascular amputation: many patients avoid both death and re-amputation at 1 year, but a substantial minority experience re-amputation, death, or both. This framing helps trainees avoid presenting prosthetic rehabilitation as the only plausible postoperative story.

Perioperative pathways should be standardized where possible. Current vascular and enhanced-recovery consensus supports structured perioperative major-amputation care, which is useful for trainees because it shifts attention from the isolated operation to the entire episode: preoperative planning, postoperative recovery, discharge readiness, and rehabilitation continuity.

Secondary prevention remains part of recovery planning. After lower-extremity revascularization, VOYAGER PAD demonstrated that low-dose rivaroxaban plus aspirin reduced a composite of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or cardiovascular death, while increasing ISTH major bleeding; for amputees with prior or concurrent revascularization, antithrombotic decisions should therefore be individualized within the broader vascular-risk and bleeding-risk plan rather than treated as a prosthetics issue alone.

TreatmentDischarge checklist: residual limb, rehab referral, and prosthetic candidacy
  • Official rehabilitation guideline supports pre-amputation, prosthetic candidacy, residual-limb and longitudinal rehab pathways.
    Action
    Interpret alongside anatomy, presentation, operative risk, and local practice before changing management.
    Clinical point
    Official rehabilitation guideline supports pre-amputation, prosthetic candidacy, residual-limb and longitudinal rehab pathways.
    Caveat
    Reflects guideline recommendations; consult the source guideline for exact class and level-of-evidence wording.
    Citation
  • Current vascular/ERAS consensus supports perioperative major-amputation pathway content.
    Action
    Interpret alongside anatomy, presentation, operative risk, and local practice before changing management.
    Clinical point
    Current vascular/ERAS consensus supports perioperative major-amputation pathway content.
    Caveat
    Based on consensus rather than comparative trial evidence; consult the source for exact wording.
    Citation

Palliative limb care is a positive care plan

Palliative limb care is not abandonment. It is an active plan for patients whose limb, physiology, prognosis, or goals make revascularization or major amputation unlikely to deliver a healed and useful outcome. Current PAD and CLTI frameworks explicitly include palliative care and shared decision-making when salvage attempts are unlikely to achieve a meaningful limb result.

A positive palliative limb plan should state what will be done, not only what will be avoided. The plan should identify the dominant problem—pain, tissue loss, infection risk, functional loss, treatment burden, or end-of-life priorities—and should align procedures, medications, wound care, and follow-up with the patient’s goals. Palliative-care consultation studies and end-of-life CLTI cohorts support building systems that make these conversations and care pathways available to frail CLTI patients rather than reserving them for the final hours of hospitalization.

Palliative care use and end-of-life CLTI support
  • Observational cohort data; findings apply to end-of-life CLTI patients and may not generalise beyond that group.
    Clinical trigger
    End-of-life CLTI cohort adds palliative/outcomes evidence distinct from technical limb-salvage sources.
    Boundary
    Observational cohort data; findings apply to end-of-life CLTI patients and may not generalise beyond that group.
    Citation
  • Based on a Medicare cohort; observational data do not establish causation and may not generalise to other populations.
    Clinical trigger
    Medicare cohort documents palliative-care underuse in CLTI, supporting non-procedure goals-of-care content.
    Boundary
    Based on a Medicare cohort; observational data do not establish causation and may not generalise to other populations.
    Citation

Underuse of palliative care in CLTI is a systems failure, not a patient preference by default. Medicare data documenting palliative-care underuse support teaching trainees to introduce palliative care as an added layer of goal-focused support, especially when repeated revascularization, major amputation, or prolonged institutional care may be discordant with the patient’s priorities.

Quality of life is a legitimate endpoint in CLTI. Patient-reported outcome syntheses in CLTI support discussing limb care in terms of daily burden, function, symptoms, and treatment trade-offs, not simply patency, wound status, or amputation-free survival. Decision-aid work similarly supports explicit trade-off communication when patients are choosing between limb salvage, amputation, and nonoperative palliative pathways.

TreatmentGoals-of-care conversation script for CLTI
  • Decision-aid source supports shared decision-making and trade-off communication for amputation decisions.
    Trigger
    Decision-aid source supports shared decision-making and trade-off communication for amputation decisions.
    Branch / Endpoint
    Citation
  • Quality of life in CLTI: systematic review and meta-analysis; primary evidence patient-reported-outcomes synthesis
    Trigger
    When weighing quality-of-life and palliative-care considerations in CLTI
    Branch / Endpoint
    Synthesis of patient-reported outcomes; findings apply to patients with CLTI and may not generalise beyond it.
    Citation

The surgeon must still be precise about vascular options. A patient may decline revascularization, may be too frail for it, may have anatomy that makes it futile, or may face a limb that cannot become functional even if flow is improved. These are different clinical states and should be documented separately, because they shape whether the palliative plan includes observation, symptom-directed care, limited procedures, or major amputation for palliation.

Guideline comparison

Palliative limb-care order set: symptoms, goals, wound care, and escalation

  1. Palliative Limb-Care 15 Year Cohort United Kingdom · 2022
    Direct palliative limb-care cohort supports when non-revascularization pathways are appropriate.
    Applies to
    Direct palliative limb-care cohort supports when non-revascularization pathways are appropriate.
    Boundary
    Single observational cohort; associations do not establish causation and may not generalise beyond that setting.
  2. Palliative-Care Consultation In CLTI Implementation Study United States · 2023
    Palliative-care consultation implementation study provides systems-of-care support for frail CLTI patients.
    Applies to
    Palliative-care consultation implementation study provides systems-of-care support for frail CLTI patients.
    Boundary
    Single-center implementation study; results may not generalise to other care settings.
Source ·

Clinical integration, follow-up, and evidence boundaries

A coherent amputation pathway integrates five decisions: whether the limb can be salvaged, whether salvage would produce a useful limb, what level is most likely to heal and function, what rehabilitation pathway is realistic, and whether palliative limb care better matches the patient’s goals. These decisions should be made by a multidisciplinary team and documented as vascular decisions, not as isolated operative events.

Follow-up should be structured around failure modes. Early problems include wound failure, medical decompensation, and discharge-plan collapse; later problems include re-amputation, contralateral limb threat, loss of rehabilitation momentum, and cardiovascular events. Registry-derived risk models, contemporary major-amputation cohorts, and re-amputation studies support using follow-up to anticipate these outcomes rather than waiting for the patient to reappear through emergency care.

Guideline comparison

Failure modes: wound failure, re-amputation, cardiovascular events, rehab dropout

  1. UK National Vascular Registry Major-Lea Risk Model United Kingdom NVR · 2020
    UK National Vascular Registry prognostic risk model for major LEA; primary evidence registry-derived risk-modeling source
    Applies to
    Risk stratification for amputation decisions and post-op planning
    Boundary
    Registry-derived risk model from a single national dataset; performance may not generalise to other populations.
  2. Danish Nationwide Major-Lea Re-Amputation Cohort Denmark National Registry · 2024
    Nationwide Danish cohort on re-amputation risk and timing after major LEA; primary evidence registry source
    Applies to
    Nationwide Danish cohort of patients undergoing major lower-extremity amputation, evaluated for re-amputation risk and timing
    Boundary
    Registry data from a single national cohort; associations do not establish causation and may not generalise beyond that setting.
Source ·

The contralateral limb and systemic vascular risk remain part of the same disease. CLTI best medical therapy, preventive foot care, and surveillance principles apply after amputation, and therapies with unestablished effectiveness as substitutes for revascularization should not distract from evidence-based vascular prevention, rehabilitation planning, and goal-concordant care.

TreatmentIntegrated follow-up map: decision, operation, discharge, rehab, and surveillance
  • Adults with CLTI, severe foot infection, ALI, or failed limb-salvage attempts.
    Action
    Treat major amputation as a deliberate, multidisciplinary CLTI decision: confirm anatomy, salvage attempts, infection control, and goals-of-care before proceeding.
    Clinical point
    The 2024 ACC/AHA PAD guideline frames major amputation as a deliberate vascular decision within the CLTI and acute-limb-ischemia subsets, requires multidisciplinary team-based care, and emphasises shared decision-making and palliative care when salvage attempts are unlikely to create a healable or useful limb.
    Caveat
    Guidance is framework-level for primary-amputation and palliative-care triggers; recommendation grades differ between guideline societies
    Citation
  • Official rehabilitation guideline supports pre-amputation, prosthetic candidacy, residual-limb and longitudinal rehab pathways.
    Action
    Interpret alongside anatomy, presentation, operative risk, and local practice before changing management.
    Clinical point
    Official rehabilitation guideline supports pre-amputation, prosthetic candidacy, residual-limb and longitudinal rehab pathways.
    Caveat
    Reflects guideline recommendations; consult the source guideline for exact class and level-of-evidence wording.
    Citation
  • Current vascular/ERAS consensus supports perioperative major-amputation pathway content.
    Action
    Interpret alongside anatomy, presentation, operative risk, and local practice before changing management.
    Clinical point
    Current vascular/ERAS consensus supports perioperative major-amputation pathway content.
    Caveat
    Based on consensus rather than comparative trial evidence; consult the source for exact wording.
    Citation

Trainees should understand the limits of the evidence they cite in consent. Trial composite endpoints are not pure amputation rates; BEST-CLI’s major adverse limb event framework includes above-ankle amputation and reintervention, while VOYAGER PAD’s limb benefit sits within a broader cardiovascular and limb composite. The correct bedside translation is not to quote these studies as direct predictors for an individual stump, but to use them to explain that revascularization, amputation, death, and major limb events compete in the same high-risk vascular population.

Evidence boundaries: composites, mortality, re-amputation, and quality of life
  • Population
    Patients with CLTI after infrainguinal revascularization where MALE and amputation endpoints frame limb-salvage outcomes.
    Intervention
    Use the MALE definition from BEST-CLI when discussing amputation outcomes after revascularization in the amputation chapter.
    Key result
    BEST-CLI established MALE (major adverse limb event including amputation) as a composite endpoint, providing the framework for distinguishing limb-salvage success from progression to amputation
    Limitation
    MALE is a composite endpoint, so its components may not all carry equal clinical weight.
    Citation

The final clinical habit is to make the plan reviewable. The chart should show the vascular indication, alternatives considered, reason salvage is being pursued or abandoned, amputation level rationale, rehabilitation expectations, medical-therapy plan, palliative-care involvement when appropriate, and follow-up triggers. This disciplined documentation protects the patient from fragmented care and helps the next clinician understand whether the goal is limb salvage, recovery after amputation, or comfort-focused limb care.

References

  1. 1.
    2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease. Circulation. 2024.
    PubMed-indexed articleClinical practice guideline2024

    2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease. Circulation. 2024. doi:10.1161/CIR.0000000000001251. PMID:38743805.

  2. 2.
    2024 ACC/AHA Lower Extremity PAD Guideline (Gornik et al, JACC 2024).
    PubMed-indexed articleClinical practice guideline2024

    2024 ACC/AHA Lower Extremity PAD Guideline (Gornik et al, JACC 2024). doi:10.1016/j.jacc.2024.02.013.

  3. 3.
    Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia. 2022.
    PubMed-indexed articleRandomized controlled trial2022

    Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia. 2022. doi:10.1056/NEJMoa2207899. PMID:36342173.

  4. 4.
    2024 ESC Guidelines for peripheral arterial and aortic diseases (Mazzolai et al, Eur Heart J 2024).
    PubMed-indexed articleClinical practice guideline2024

    2024 ESC Guidelines for peripheral arterial and aortic diseases (Mazzolai et al, Eur Heart J 2024). doi:10.1093/eurheartj/ehae179.

  5. 5.
    Global Vascular Guidelines on CLTI (Conte et al, J Vasc Surg 2019) DOI: 10.1016/j.jvs.2019.02.016
    PubMed-indexed articleClinical practice guideline2019
  6. 6.
    Amputation Mortality SR 2021.
    PubMed-indexed articleMeta-analysis / systematic review2021

    Amputation Mortality SR 2021. doi:10.1053/j.jfas.2020.06.027. PMID:33509714.

  7. 7.
    Major LEA Reamputation 2024.
    PubMed-indexed article2024

    Major LEA Reamputation 2024. doi:10.2340/17453674.2024.39963. PMID:38305435.

  8. 8.
    Prognostic Risk Modelling Nvr 2020.
    PubMed-indexed article2020

    Prognostic Risk Modelling Nvr 2020. doi:10.1016/j.ejvs.2019.12.006. PMID:31883800.

  9. 9.
    QOL CLTI SR 2022.
    PubMed-indexed articleMeta-analysis / systematic review2022

    QOL CLTI SR 2022. doi:10.1016/j.ejvs.2022.07.051. PMID:35952907.

  10. 10.
    Through-knee versus above-knee amputation for vascular and non-vascular major lower-limb amputation. Cochrane Database Syst Rev. 2022.
    PubMed-indexed articleReview2022

    Through-knee versus above-knee amputation for vascular and non-vascular major lower-limb amputation. Cochrane Database Syst Rev. 2022. doi:10.1002/14651858.CD013839.pub2. PMID:34904714.

  11. 11.
    Development of the AMPDECIDE Decision Aid to Facilitate Shared Decision Making in Patients Facing Amputation Secondary to Chronic Limb Threatening Ischemia. 2024.
    PubMed-indexed articleReview2024

    Development of the AMPDECIDE Decision Aid to Facilitate Shared Decision Making in Patients Facing Amputation Secondary to Chronic Limb Threatening Ischemia. 2024. doi:10.1016/j.jss.2024.03.011. PMID:38714006.

  12. 12.
    Functional Outcomes After the Prosthetic Training Phase of Rehabilitation After Dysvascular Lower Extremity Amputation. 2015.
    PubMed-indexed articleRegistry / cohort2015

    Functional Outcomes After the Prosthetic Training Phase of Rehabilitation After Dysvascular Lower Extremity Amputation. 2015. doi:10.1016/j.pmrj.2015.05.006. PMID:25978948.

  13. 13.
    End of life care in chronic limb threatening ischemia: A retrospective cohort study. 2024.
    DOI publisher routeRegistry / cohort2024

    End of life care in chronic limb threatening ischemia: A retrospective cohort study. 2024. doi:10.1016/j.jvsvi.2024.100141.

  14. 14.
    A framework for perioperative care in lower extremity major limb amputation: a consensus statement by the Enhanced Recovery After Surgery (ERAS) Society and Society for Vascular Surgery. 2024.
    DOI publisher routeClinical practice guideline2024

    A framework for perioperative care in lower extremity major limb amputation: a consensus statement by the Enhanced Recovery After Surgery (ERAS) Society and Society for Vascular Surgery. 2024. doi:10.1016/j.jvsvi.2024.100156.

  15. 15.
    Major lower extremity amputation: a contemporary analysis from an academic tertiary referral centre in a developing community. 2019.
    PubMed-indexed articleRegistry / cohort2019

    Major lower extremity amputation: a contemporary analysis from an academic tertiary referral centre in a developing community. 2019. doi:10.1186/s12893-019-0637-y. PMID:31722699.

  16. 16.
    Integration of palliative care consultation into the management of patients with chronic limb-threatening ischemia. 2023.
    PubMed-indexed articleRegistry / cohort2023

    Integration of palliative care consultation into the management of patients with chronic limb-threatening ischemia. 2023. doi:10.1016/j.jvs.2022.12.069. PMID:37088444.

  17. 17.
    A single center's 15-year experience with palliative limb care for chronic limb threatening ischemia in frail patients. 2022.
    PubMed-indexed articleRegistry / cohort2022

    A single center's 15-year experience with palliative limb care for chronic limb threatening ischemia in frail patients. 2022. doi:10.1016/j.jvs.2021.09.032. PMID:34627958.

  18. 18.
    Poor utilization of palliative care among Medicare patients with chronic limb-threatening ischemia. 2023.
    PubMed-indexed articleRegistry / cohort2023

    Poor utilization of palliative care among Medicare patients with chronic limb-threatening ischemia. 2023. doi:10.1016/j.jvs.2023.02.023. PMID:37088446.

  19. 19.
    Clinical Practice Guidelines for the Rehabilitation of Lower Limb Amputation: An Update from the Department of Veterans Affairs and Department of Defense. 2019.
    PubMed-indexed articleClinical practice guideline2019

    Clinical Practice Guidelines for the Rehabilitation of Lower Limb Amputation: An Update from the Department of Veterans Affairs and Department of Defense. 2019. doi:10.1097/PHM.0000000000001213. PMID:31419214.

  20. 20.
    Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg. 2019.
    DOI publisher routeClinical practice guideline2019

    Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg. 2019. doi:10.1016/j.ejvs.2019.05.006.

  21. 21.
    VOYAGER PAD (Bonaca et al, N Engl J Med 2020).
    PubMed-indexed articleRandomized controlled trial2020

    VOYAGER PAD (Bonaca et al, N Engl J Med 2020). doi:10.1056/NEJMoa2000052.

  22. 22.
    Bradbury AW, Moakes CA, Popplewell M, et al. A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. Lancet. 2023;401(10390):1798-1809.
    PubMed-indexed articleRandomized controlled trial2023
  23. 23.
    AMPREDICT MoRe (Norvell et al, EJVES 2025).
    PubMed-indexed articleRegistry / cohort2025

    AMPREDICT MoRe (Norvell et al, EJVES 2025). doi:10.1016/j.ejvs.2025.02.016.

  24. 24.
    VASCUNET Report on International Amputation Variation (Behrendt et al, EJVES 2018).
    PubMed-indexed articleRegistry / cohort2018

    VASCUNET Report on International Amputation Variation (Behrendt et al, EJVES 2018). doi:10.1016/j.ejvs.2018.04.017.

Educational use only

AI assists this editorial workflow. Published updates are human-reviewed before publication.

Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.

Verify clinically relevant information against primary sources and current guidelines.